Striatal cannabinoid CB1 receptor mRNA expression is decreased in the reserpine-treated rat model of Parkinson's disease

Experimental Neurology

Volumn 169, Issue 2, 2001, Pages 400-406

  Silverdale, M A ^a   McGuire, S ^a   McInnes, A ^a   Crossman, A R ^a   Brotchie, J M ^a  

^a UNIVERSITY OF MANCHESTER   (United Kingdom)

Author keywords

Cannabinoids; CB1 receptor; In situ hybridization; Parkinson's disease; Rat; Reserpine; Striatum

Indexed keywords

1,2,3,6 TETRAHYDRO 1 METHYL 4 PHENYLPYRIDINE; 4 AMINOBUTYRIC ACID; CANNABINOID; CANNABINOID 1 RECEPTOR; CANNABINOID RECEPTOR; CANNABINOID RECEPTOR ANTAGONIST; DOPAMINE; DOPAMINE 2 RECEPTOR STIMULATING AGENT; MESSENGER RNA; NEUROTRANSMITTER; OXIDOPAMINE; QUINPIROLE; RESERPINE; RIMONABANT;

AKINESIA; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BASAL GANGLION; CONTROLLED STUDY; DOPAMINERGIC SYSTEM; DRUG POTENTIATION; GENE EXPRESSION; IN SITU HYBRIDIZATION; MALE; NEUROLOGIC DISEASE; NEUROTRANSMISSION; NONHUMAN; PARKINSON DISEASE; PARKINSONISM; PRIORITY JOURNAL; RAT;

EID: 0034982493     PISSN: 00144886     EISSN: None     Source Type: Journal    
DOI: 10.1006/exnr.2001.7649     Document Type: Article

References (40)

1. The functional anatomy of disorders of the basal ganglia
2. Cannabinoids: Influence on Neurotransmitter uptake in rat brain synaptosomes
3. Chemical signalling in the globus pallidus in parkinsonism
4. Novel approaches to the symptomatic treatment of parkinsonian syndromes: Alternatives and adjuncts to dopamine-replacement
5. 3, 4-Dihydroxyphenylalanine and 5-hydroxytryptophan as reserpine antagonists
6. Pharmacological characteristics of tremor, rigidity and hypokinesia induced by reserpine in rat
7. Primate models of movement disorders of basal ganglia origin
8. Isolation and structure of a brain constituent that binds to the cannabinoid receptor
9. Formation and inactivation of endogenous cannabinoid anandamide in central neurons
10. The role of endocannabinoids in the control of movement and the generaton of parkinsonian symptoms
11. A role for endocannabinoids in the control of movement and generation of symptoms in Parkinson's disease
12. Endocannabinoids: Endogenous cannabinoid receptor ligands with neuromodulatory action
13. Topographical organization of opioid peptide precursor gene expression following repeated apomorphine treatment in the 6-hydroxydopamine- lesioned rat
14. Postsynaptic dopamine/adenosine interaction. I. Adenosine analogues inhibit dopamine D2-mediated behaviour in short-term reserpinized mice
15. The neostriatal mosaic: Multiple levels of compartmental organization
16. D1 and D2 dopamine receptor-regulated gene expression of striatonigral and striatopallidal neurons
17. Dopamine activation of endogenous cannabinoid signaling in dorsal striatum
18. Modulation of neurotransmission by cannabionoids in the basal ganglia
19. Anxiolytic effect of cannabidiol derivatives in the elevated plus-maze
20. Neuronal localization of cannabinoid receptors in the basal ganglia of the rat
21. NMDA antagonists potentiate antiparkinsonian actions of L-dopa in monoamine-depleted rats
22. Quinpirole hydrochloride, a potential anti-parkinsonism drug
23. Bilateral projections from precentral motor cortex to the putamen and other parts of the basal ganglia. An autoradiographic study in Macaca fascicularis
24. Distribution of neuronal cannabinoid receptor in the adult rat brain: A comparative receptor binding radioautography and in situ hybridisation histochemistry
25. Dopaminergic regulation of cannabinoid receptor mRNA levels in the rat caudate-putamen: An in situ hybridization study
26. Paradoxical action of the cannabinoid WIN 55, 212-2 in stimulated and basal cyclic AMP accumulation in rat globus pallidus slices
27. The cannabinoid receptor agonist WIN 55, 212-2 reduces D2 but not D1, dopamine receptor mediated alleviation of akinesia in the reserpine treated rat model of Parkinson's disease
28. On the role of enkephalin cotransmission in the GABAergic striatal efferents to the globus pallidus
29. Activation of the cannabinoid receptor by delta 9 terashydrocannabinol reduces gamma aminobutyric acid uptake in the globus pallidus
30. Structure of a cannabinoid receptor and functional expression of the cloned cDNA
31. Identification of an endogenous 2-monoglyceride, present in canine gut, that binds to cannabinoid receptors
32. Neural mechanisms underlying parkinsonian symptoms based upon regional uptake of 2-deoxyglucose in monkeys exposed to 1-methyl-4-phenyl- 1, 2, 3, 6-tetrahydropyridine
33. Gamma-aminobutyric acid and benzodiazepine receptor changes induced by unilateral 6-hydroxydopamine lesions of the medial forebrain bundle
34. Enhancement by chlordiazepoxide of catalepsy induced in rats by intravenous or intrapallidal injections of enantiomeric cannabinoids
35. Excitotoxic lesions of the septum produce anxiolytic effects in the elevated plus-maze and the shock-probe burying tests
36. Parkinson's disease: Clinical features
37. A second endogenous cannabinoid that modulates long-term potentiation
38. The mode of action of bromocriptine following pretreatment with reserpine and alpha-methyl-p-tyrosine in rats
39. Chronic L-DOPA treatment increases striatal cannabinoid CB1 receptor mRNA expression in 6-hydroxydopamine-lesioned rats